This disclosure relates to extracorporeal fluid circuits and related components.
Hemodialysis removes toxic substances and metabolic waste from the bloodstream using an extracorporeal circuit with components designed to perform ultrafiltration and diffusion on the blood. Before the blood is returned to the body, air bubbles can be removed from the blood to help prevent embolisms.
In one aspect, an extracorporeal medical fluid circuit component is described. The component includes a vent assembly. A vent structure adjacent to a micro-porous membrane forms the assembly. The vent structure is porous and is capable of changing color when the vent structure is moistened. The component is capable of being used in an extracorporeal medical fluid circuit.
In another aspect, a transducer protector includes a body that defines a fluid pathway. A vent assembly is disposed in the fluid pathway. The vent assembly includes a vent structure and a micro-porous membrane. The vent structure is porous and is capable of changing color when moistened. The transducer protector is capable of being connected in fluid communication with a fluid circuit and a pressure transducer such that the vent assembly inhibits liquid flowing in the fluid circuit from contacting the pressure transducer.
In a further aspect, an extracorporeal medical fluid circuit apparatus, e.g., for removing air from a bodily liquid in extracorporeal circuitry used in a hemodialysis machine, is described. The apparatus includes a chamber having a fluid entry port, and a fluid exit port. The apparatus also includes a vent assembly. The vent assembly includes a micro-porous membrane and a vent structure adjacent to the micro-porous membrane. The vent structure is formed of a porous material that is capable of changing color when moistened. The fluid entry port and the fluid exit port are arranged to allow liquid to pass through the chamber from the entry port to the exit port so as to fill the chamber with the liquid, and the vent assembly is arranged to allow gas to exit the chamber as the liquid passes through the chamber.
In yet another aspect, a system (e.g., a dialysis system, e.g., a hemodialysis system) is described. The system includes a machine body, a pump on the machine body, and fluid circuitry (e.g., tubes) in fluid communication with the pump. The pump is configured to pull fluid from a patient and push fluid through the fluid circuitry. The system also includes a vent assembly in fluid communication with the fluid circuitry. The vent assembly includes a micro-porous membrane and a vent structure adjacent to the micro-porous membrane. The vent structure is formed of a porous material that is capable of changing color when moistened.
Embodiments of the disclosed methods, systems and devices may include one or more of the following features.
In some embodiments, the porous material is capable of swelling when moistened. For example, the porous material can include (e.g., be impregnated with) a swelling agent, such as carboxymethylcellulose, methyl-ethyl-cellulose or other similar swelling agent, that is capable of swelling when moistened.
The vent structure can include a color change additive such as powdered or granulated dye, e.g., food dye, or a pH indicator, such as bromophenol blue.
The vent structure can include about 0.05% by weight to about 2% by weight of a color change additive.
The vent structure can include a polymer such as polyethylene (e.g., high density polyethylene (HDPE), polypropylene, or polystyrene.
The vent structure can include a blend of a polymer (e.g., polyethylene, polypropylene, or polystyrene), a swelling agent (e.g., carboxymethylcellulose), and a color change additive.
The color change additive can be covalently bonded to the swelling agent.
The vent structure can include a blend of a polymer (e.g., polyethylene, polypropylene, or polystyrene), a swelling agent (e.g., carboxymethylcellulose), and a pH indicator (e.g., bromophenol blue).
The pH indicator can be covalently bonded to the swelling agent.
The vent structure can have an average pore size of about 15 microns to about 45 microns.
The micro-porous membrane can have an average pore size of about 0.05 to about 0.45 microns (e.g., about 0.22 microns or about 0.2 microns).
The micro-porous membrane can be hydrophobic.
The extracorporeal medical fluid circuit component can be configured for use in a device adapted to remove air from blood.
The extracorporeal medical fluid circuit component can be configured for use in a transducer protector.
The extracorporeal medical fluid circuit component can be configured for use in a blood circuit.
The dialysis system can include an electro-optical assembly arranged to detect a change in color of the vent structure.
The electro-optical assembly can include a light emitter arranged to emit light towards the vent structure, and a light detector arranged to detect light reflected off of the vent structure.
The system can also include a controller in electrical communication with the electro-optical assembly and the pump. The controller can be configured to halt operation of the pump in response to receiving a signal from the electro-optical assembly indicating that the vent structure has changed color.
The system can also include a speaker, and a controller in electrical communication with the electro-optical assembly and the speaker. The controller can be configured to sound an audible alarm through the speaker in response to receiving a signal from the electro-optical assembly indicating that the vent structure has changed color. The controller can be configured to sound an alarm in response to receiving a signal from the electro-optical assembly indicating that the light detector detected reflected light having a wavelength that falls within a predetermined range (e.g., 440 nm to about 490 nm). The actual wavelength range will match that of the changed vent structure color.
The system can also include a display, and a controller in electrical communication with the electro-optical assembly and the display. The controller can be configured to provide a visual alarm on the display in response to receiving a signal from the electro-optical assembly indicating that the vent structure has changed color.
The system can include a pressure transducer, and a transducer protector disposed between, and in fluid communication with, the fluid circuitry and the pressure transducer. The transducer protector can include the vent assembly.
The system can include a chamber in fluid communication with the fluid circuitry. The chamber can include a fluid entry port and a fluid exit port. The fluid circuitry can be configured to allow liquid to pass through the chamber from the entry port the exit port so as to fill the chamber with the liquid. The vent assembly can be arranged to allow gas to exit the chamber through the vent assembly as the liquid passes through the chamber.
Embodiments can include one or more of the following advantages.
In some embodiments, a visual indication is provided when a membrane failure has occurred.
In some cases, multiple functions such as sealing (e.g., automatic self-sealing) and alerting (e.g., visual indication) are provided in a single device.
In certain embodiments, electro-optical detection helps to ensure that a user is alerted quickly in the event of a membrane failure.
In some embodiments, automatic shut-off of the system occurs when a membrane failure is detected, which can help to inhibit contamination of system components.
Other aspects, features, and advantages are in the description, drawings, and claims.
A fluid circuit, such as an extracorporeal fluid circuit used in filtering blood from a patient during hemodialysis, can be provided with one or more self-sealing/color changing vent assemblies to inhibit (e.g., prevent) fluids flowing within the circuit from coming into contact with the surrounding, external atmosphere and/or coming into contact with, and possibly contaminating, neighboring devices. The self-sealing/color changing vent assemblies can also inhibit (e.g., prevent) foreign particles and organisms from the external atmosphere from coming into contact with liquid flowing within the fluid circuit.
The self-sealing/color changing vent assemblies generally include a micro-porous membrane and a vent structure. In use, the micro-porous membrane is disposed between the vent structure and liquid flowing within a fluid circuit. The micro-porous membrane normally inhibits (e.g., prevents) the liquid flowing within the fluid circuit from contacting the vent structure, while allowing gases, such as air, to pass through. The vent structure is formed of a porous material that normally allows gases to pass through. The vent structure is capable of swelling and changing color when moistened. In the event that the micro-porous membrane ruptures, blood flowing within the fluid circuit will come into contact with the vent structure causing the vent structure to swell and self-seal, inhibiting the passage of fluids, including gases therethrough. As a result of the blood coming into contact with the vent structure, the vent structure also changes color, thereby providing a visual indication that the vent structure has self-sealed.
System Overview
Referring to
The extracorporeal circuit 100 also includes an external transducer protector 140 that is mounted externally to the dialysis machine 50 between, and in communication with, the drip chamber 115 and the internal transducer protector 132. The external transducer protector 140 carries a self-sealing vent assembly 141 (
After exiting the drip chamber 115, the blood then flows through tubing 117 to a dialyzer 170, which separates waste products from the blood.
After passing through the dialyzer 170, the blood flows through venous tubing 180 towards an air release chamber 230 in which gas (e.g., air) in the blood can escape before the blood continues to the patient 105. During treatment, should air be present in the blood, the blood with air bubbles flows in through the bottom of the air release chamber 230. The upper motion of the blood is impeded by gravity and becomes stagnant, while the air continues to the top of the chamber 230 where it is vented out to the atmosphere through another self-sealing vent assembly 270. The vent assembly 270 of the chamber 230 includes a micro-porous membrane 260 (
After leaving the chamber 230, the blood travels through a venous line 190 and back to the patient 105.
External Transducer Protector
Referring to
The micro-porous membrane 144 allows gas (e.g., air) to pass through the vent assembly compartment 142, but impedes the flow of liquid, thereby inhibiting or preventing the blood from directly contacting, and possible contaminating, the component (e.g, the internal transducer protector 132, the dialysis machine 50, and the pressure transducer 130) on the opposite side of the vent assembly compartment 142. The micro-porous membrane 144 can also help to inhibit (e.g., prevent) foreign particles and organisms from entering the extracorporeal circuit 100 from the transducer side of the vent assembly compartment 142.
The micro-porous membrane 144 is hydrophobic. For example, in some embodiments, the micro-porous membrane 144 includes a hydrophobic material, such as polytetrafluoroethylene (PTFE) (e.g., expanded polytetraflouroethylene (ePTFE)) backed by a mesh material. In some embodiments, the membrane 144 is a fibrous carrier with a matted and woven layer on top of which ePTFE or other micro-porous material is applied. A suitable membrane has an average pore size of about 0.05 to about 0.45 microns (e.g., about 0.22 microns or about 0.2 microns). Suitable membranes are available from Pall Corporation, East Hills, N.Y., under the Versapor® mark and from W. L. Gore & Associates, Inc., Newark, Del.
The self-sealing vent structure 146 is a solid porous block, having an average pore size of about 5 to about 45 microns, that allows air to pass through the vent assembly compartment 142. In some embodiments, the self-sealing vent structure 146 is formed of a blend of polyethylene (e.g., high density polyethylene (HDPE) and carboxymethylcellulose (CMC), a blend of polystyrene and methyl-ethyl-cellulose or of polypropylene- or polyethylene-based porous material. The vent structure 146 can include about 80% to about 95% by weight high density polyethylene and about 5% to about 20% by weight carboxymethylcellulose.
The self-sealing vent structure 146 also includes a color change additive that is capable of changing color when placed in contact with liquid. The solid porous block (e.g., of polyethylene and carboxymethylcellulose) may be impregnated with the color change additive during manufacture. In some embodiments, the color change additive is covalently bonded to carboxymethylcellulose of the vent structure 146. The color change additive can be a pH indicator, such as bromophenol blue, that changes color when it comes into contact with water. Alternatively or additionally, the color change additive can be a dye, e.g., a food dye, e.g., in powdered or granular form. The vent structure may contain about 0.05% to about 2% by weight color change additive. The vent structure may be formed, for example, by depositing a mixture of high density polyethylene powder, carboxymethylcellulose powder, and powdered dye, in the desired proportions, into a mold and applying heat and pressure to the mixture to form a solid porous block which takes the shape of the mold.
Referring to
The first and second parts 150, 152 of the external transducer protector 140 each include an associated sidewall 154, 155. The sidewalls 154, 155 of the respective first and second parts 150, 152 help to retain the micro-porous membrane 144 and the self-sealing vent structure 146 within the vent assembly compartment 142 following assembly. As illustrated in
In use, if a rupture of the micro-porous membrane 144 occurs, blood flowing in the extracorporeal fluid circuit 100 may come into contact with the vent structure 146 causing the vent structure 146 to seal and change color, and, by sealing will change pressure to the pressure transducer 130 in the dialysis machine 50. Referring to
Air Release Chamber
Referring to
The ports 240, 242 are holes in the chamber 230 which can be in fluid communication with tubular shaped extensions. The extensions are able to be connected to tubes, such as by pressure fitting or bonding. The extensions can be integrally formed with the chamber 230 or subsequently attached to the chamber 230, such as by bonding or welding.
At the top region 236 of the chamber 230 is the self-sealing vent assembly 270. The self-sealing vent assembly 270 includes the micro-porous membrane 260 and the vent structure 264. The assembly with the vent structure 264 and micro-porous membrane 260 may provide reduced condensation or minimize condensation on the micro-porous membrane 260. The micro-porous membrane 260 allows gas (e.g., from air bubbles in the blood) to vent from the chamber 230. Pores in the micro-porous membrane 260 are small enough to keep foreign particles and organisms from entering the chamber 230 from the outside air.
In some implementations, the membrane 260 includes a hydrophobic material, such as polytetrafluoroethylene (PTFE) (e.g., expanded polytetraflouroethylene (ePTFE)). In some embodiments, the membrane 260 is a fibrous carrier with a matted and woven layer on top of which PTFE or other micro-porous material is applied. The hydrophobic micro-porous membrane 260 keeps liquid from leaking out of the chamber 230 when the chamber 230 is substantially filled with liquid and allow air to pass through. A suitable membrane has an average pore size of about 0.05 microns to about 0.45 microns (e.g., about 0.22 microns, about 0.2 microns). Suitable membranes are available from Pall Corporation, East Hills, N.Y., under the Versapor® mark and from W. L. Gore & Associates, Inc., Newark, Del.
The vent structure 264 is a solid porous block, having an average pore size of about 15 microns to about 45 microns, that allows air to pass through and escape from the chamber. The vent structure 264 is also a self-sealing vent structure. In some implementations, the vent structure 264 is formed of a blend of polyethylene (e.g., high density polyethylene (HDPE) and carboxymethylcellulose (CMC), a blend of polystyrene and methyl-ethyl-cellulose or of polypropylene- or polyethylene-based porous material. The vent structure 264 can include about 80% to about 95% by weight high density polyethylene and about 5% to about 20% by weight carboxymethylcellulose.
The vent structure 264 also includes a color change additive that is capable of changing color when placed in contact with liquid. The solid porous block (e.g., of polyethylene and carboxymethylcellulose) that forms the vent structures 264 may be impregnated with the color change additive during manufacture. In some embodiments, the color change additive is covalently bonded to the vent structure. For example, the color change additive can include a pH indicator, such as bromophenol blue, that is covalently bonded to carboxymethylcellulose of the vent structure 264. Alternatively or additionally, the color change additive can include a dye, e.g., a food dye, e.g., in powdered or granular form. The vent structure may contain about 0.05% to about 2% by weight color change additive. The vent structure may be formed, for example, by depositing a mixture of high density polyethylene powder, carboxymethylcellulose powder, and powdered food dye, in the desired proportions, into a mold and applying heat and pressure to the mixture to form a solid porous block which takes the shape of the mold.
When the vent structure 264 comes into contact with liquid, e.g., humidity or moisture, the swelling agent (e.g., cellulose component, e.g., carboxymethylcellulose) of the vent structure expands, thereby closing off the pores in the polymer component (e.g., high density polyethylene) of the vent structure 264. In addition, the color of the vent structure 264 will change giving a visual indication that liquid has come into contact with the vent structure 264. The vent structure 264 is mounted adjacent to and just above the membrane 260 so that the hydrophobic membrane 260 is located between the vent structure 264 and the chamber 230. The vent structure 264 inhibits (e.g., prevents) condensation from accumulating on and contacting the membrane 260. In some embodiments, the vent structure 264 directly contacts the membrane 260. The vent structure 264 can be substantially disc shaped or can be another shape that is compatible with a chamber on which the vent structure 264 is mounted. In embodiments, the vent structure 264 is about 0.1 mm to about 10 mm thick.
When the chamber 230 is filled with blood, inhibiting (e.g., preventing) the protein in the blood from accumulating on the membrane 260 can maintain the hydrophobic characteristic of the membrane 260. Whole blood can be kept from the membrane 260 by providing a barrier between the blood and the membrane 260, such as a liquid barrier 268, as described further below. The height of the chamber 230 is sufficient to maintain this barrier 268 and inhibits (e.g., prevents) the liquid above the barrier 268 from substantially mixing with liquid below the barrier 268.
The chamber is formed of a material suitable for medical devices, that is, a medical grade material. Plastics, such as polyvinylchloride, polycarbonate, polyolefins, polypropylene, polyethylene or other suitable medical grade plastic can be used because of their ease of manufacturing, ready availability and disposable nature. The chamber is formed, such as by molding, for example, extruding, blow molding or injection molding. The chamber can be formed of a transparent or clear material so that the liquid flowing through the chamber can be observed.
The construction of the vent assembly 270 is described with respect to the following figures. Referring to
Referring to
Referring to
Referring to
Referring to
Although the vent assemblies described herein are shown as cylindrical, the assembly can have other shapes as well, such as rectangular, polygon, triangular or other suitable cross sectional shapes. Also, the vent assembly can have a threaded portion so that the assembly can be, for example, screwed into the air release chamber. Alternatively, the vent assembly can be welded, adhered with epoxy or otherwise fastened to the top of the chamber.
Methods of Operation
Referring to
The second liquid, such as a bodily fluid, for example, blood, is then introduced into the system (step 418). The blood follows the same route as the saline and, for the most part, pushes the saline through the circuit 100. When the blood enters the chamber 230, the blood forces the saline at the bottom of the chamber 230 through the exit port (step 422). However, the blood does not displace all of the saline within the chamber 230. Because of the height of the chamber 230, the blood enters the chamber 230 and only traverses part of the height of the chamber 230 before flowing back down along flow path 274 to the exit port (as shown in the air release chamber formed of transparent material in
The saline keeps the blood from contacting the filter 260. However, a percentage of blood can be present in the saline without hindering the operation of the circuit 100. That is, the saline need not be completely free from blood for the air release chamber 230 to both allow gas (e.g., from air bubbles in the blood) to vent from the circuit 100 and retain the liquid in the circuit 100. The solution that is mostly saline substantially protects the membrane 260 from becoming coated with protein. If the chamber 230 is sufficiently elongated, the blood does not mix with the saline at the top portion of the chamber 230 because the saline remains relatively stagnant as the blood flows through the chamber 230.
Any unbound gas, or air, that is in the blood, such as air that is introduced by the dialyzer 170 or air that comes out of solution from the blood, rises as tiny air bubbles within the blood and saline until the air eventually vents out through the vent assembly 270, including the micro-porous filter 260 and the vent structure (step 430). With a dam 248 inside of the chamber 230, the blood travels up and over the dam 248 rather than straight across the bottom of the chamber 230 out the exit port 242. By directing the flow of blood upwards, the blood with air is not able to flow in and directly back out of the chamber 230 without flowing upwards to at least a height greater then the height of the dam 248. The surface area of the dam 248 and the inner walls of the chamber 230 enables air, including microbubbles, to separate from the blood and exit the circuit 100 through the micro-porous membrane 260.
Throughout the circuit, the blood flows without there being a substantial air-blood interface. Although the blood does not come into contact with air and thus clotting is less likely to occur, the blood can pass through an optional filter in the chamber. In some implementations, after exiting the chamber, the blood passes by or through one or more sensors, such as temperature or air detecting sensors.
Other Embodiments
While certain embodiments have been described above, other embodiments are possible.
In some embodiments, a color change of a color changing self-sealing vent structure can be detected electro-optically. For example, as illustrated in
As shown in
Under the control of the host controller 54, the light emitter 514 emits light 522 towards the vent structure 146. At least a portion of the light is reflected back toward the light detector 516. The light detector 516 is tuned to receive reflected light 524 corresponding to the wavelength of the color changing vent structure 146. For example, where the vent structure 146 is capable of changing from substantially white to a shade of blue when moistened, the light detector 516 is tuned to receive reflected light having a wavelength of about 440 nm to about 490 nm. In response to detecting the reflected light 524, the light detector 516 produces a corresponding electrical signal which is processed and delivered, via the interface electronics, to the host controller 54.
The host controller 54 can be configured to provide a visual alert (e.g., on a display 58 in electrical communication with the controller 54), sound an audible alarm (e.g., through a speaker 60 in electrical communication with the controller 54) and/or automatically shut-off the dialysis machine 50 (e.g., halt operation of the pump 160) in response to receiving a signal from the electro-optical assembly 510 indicating that color change has been detected.
Alternatively or additionally, an electro-optical assembly 550 can be provided for detecting a color change of the vent structure 264 that is in communication with the air release chamber 230. Referring to
Under the control of the host controller 54, the light emitter 554 emits light 562 towards the vent structure 264. At least a portion of the light is reflected back toward the light detector 556. The light detector 556 is tuned to receive reflected light 554 corresponding to the wavelength of the color changing vent structure 264. For example, where the vent structure 264 is capable of changing from substantially white to a shade of blue when moistened, the light detector 556 is tuned to receive reflected light having a wavelength of about 440 nm to about 490 nm. In response to detecting the reflected light 554, the light detector 556 produces a corresponding electrical signal which is processed and delivered, via the interface electronics, to the host controller 54 where it is evaluated to determine the status (i.e., whether or not a color change has occurred) of the vent structure 264.
The host controller 54 can be configured to provide a visual alert (e.g., on a display 58 in electrical communication with the controller 54), sound an audible alarm (e.g., through a speaker 60 in electrical communication with the controller) and/or automatically shut-off the dialysis machine 50 (e.g., halt operation of the pump 160) in response to receiving a signal from the electro-optical assembly 550 indicating that a color change has been detected.
In some implementations, the vent assembly can include a multilayer self-sealing vent structure, where different layers of the vent structure have differing self-sealing (e.g., swelling) characteristics and where one or more of the layers are capable of changing color when exposed to moisture. For example,
The second porous layer 266 also includes a color change additive that is capable of changing color when placed in contact with liquid. The solid porous block (e.g., of polyethylene and carboxymethylcellulose) that forms the second porous layer 266 may be impregnated with the color change additive during manufacture. In some embodiments, the color change additive is covalently bonded to the second porous layer 266. For example, the color change additive can include a pH indicator, such as bromophenol blue, that is covalently bonded to carboxymethylcellulose of the second porous layer 266. Alternatively or additionally, the color change additive can include a dye, e.g., a food dye, e.g., in powdered or granular form. Second porous layer 266 may contain about 0.05% to about 2% by weight color change additive. The second porous layer 266 may be formed, for example, by depositing a mixture of high density polyethylene powder, carboxymethylcellulose powder, and powdered food dye, in the desired proportions, into a mold and applying heat and pressure to the mixture to form a solid porous block which takes the shape of the mold.
During use, condensation can, for example, form within the vent assembly. The first porous layer 265 allows for a small amount of condensation to be compensated for without activation of the self-sealing property of the second porous layer 266. The first porous layer 265, being relatively less responsive to the presence of moisture (i.e., as compared to the second porous layer 266) slows the progression of moisture from within the chamber 230 toward the second porous layer 266. The first porous layer 265 provides additional surface area (e.g., within pores) where condensation can be pulled out of the air exiting the vent assembly 270′ before it reaches self-sealing, second porous layer 266. Thus, small amounts of humidity and moisture (e.g., condensation) from within the air release chamber 230 can be compensated for without triggering closure of the vent structure 264′. In the event that the second porous layer 266 is exposed to moisture (e.g., in the event of a membrane rupture), the second porous layer 266 will seal, thereby closing off the vent structure 264′. The second porous layer 266 will also change color when exposed to liquid, and thus a visual indication that the vent structure 146 has sealed will be provided.
In some embodiments, the first porous layer 265 may also include a color change additive, such as described above, that is capable of changing color when placed in contact with liquid. Thus, a visual indication can be provided when first porous layer 265 is exposed to moisture. This may help to provide an early warning of a possible membrane failure. In some embodiments, the shape of the air release chamber is approximately elongate. In some implementations, such as those shown in
While air release chambers having entry and exit ports in a bottom region of the chamber have been described, in other implementations, as shown in
Although an embodiment of a extracorporeal circuit has been described in which an arterial pressure sensor assembly is arranged to measure a post-pump arterial pressure, in some embodiments, as illustrated in
Although certain implementations of a vent assembly have been described, in other implementations a different type of assembly can be formed. Referring to
Although the vent assemblies described herein are shown as cylindrical, the assembly can have other shapes as well, such as rectangular, polygon, triangular or other suitable cross sectional shapes. Also, the vent assembly can have a threaded portion so that the assembly can be, for example, screwed into the air release chamber. Alternatively, the vent assembly can be welded, adhered with epoxy or otherwise fastened to the top of the chamber.
While air release chambers and transducer protectors have been described, the vent assemblies can be used in other extracorporeal fluid circuit components.
The components described herein can be used with other liquids, such as plasma, water, saline, and other medical fluids. Additionally, liquids other than saline can be used to prime the system. Other embodiments are within the scope of the following claims.
Number | Name | Date | Kind |
---|---|---|---|
3946731 | Lichtenstein | Mar 1976 | A |
3982538 | Sharpe | Sep 1976 | A |
3985135 | Carpenter et al. | Oct 1976 | A |
3996027 | Schnell et al. | Dec 1976 | A |
4014206 | Taylor | Mar 1977 | A |
4026669 | Leonard et al. | May 1977 | A |
4061031 | Grimsrud | Dec 1977 | A |
4137160 | Ebling et al. | Jan 1979 | A |
4187057 | Xanthopoulos | Feb 1980 | A |
4231370 | Mroz et al. | Nov 1980 | A |
4370983 | Lichtenstein | Feb 1983 | A |
4459139 | vonReis et al. | Jul 1984 | A |
4488961 | Spencer | Dec 1984 | A |
4530759 | Schal | Jul 1985 | A |
4572724 | Rosenberg et al. | Feb 1986 | A |
4590227 | Nakamura et al. | May 1986 | A |
4643713 | Viitala | Feb 1987 | A |
4662906 | Matkovich et al. | May 1987 | A |
4695385 | Boag | Sep 1987 | A |
4702675 | Aldrovandi et al. | Oct 1987 | A |
4702829 | Polaschegg et al. | Oct 1987 | A |
4888004 | Williamson | Dec 1989 | A |
4997464 | Kopf | Mar 1991 | A |
5061236 | Sutherland et al. | Oct 1991 | A |
5330425 | Utterberg | Jul 1994 | A |
5425173 | Moss et al. | Jun 1995 | A |
5441636 | Chevallet et al. | Aug 1995 | A |
5460490 | Carr et al. | Oct 1995 | A |
5498338 | Kruger et al. | Mar 1996 | A |
5540265 | Polaschegg et al. | Jul 1996 | A |
5578070 | Utterberg | Nov 1996 | A |
5591344 | Kenley et al. | Jan 1997 | A |
5614677 | Wamsiedler et al. | Mar 1997 | A |
5628908 | Kamen et al. | May 1997 | A |
5643205 | Utterberg | Jul 1997 | A |
5651893 | Kenley et al. | Jul 1997 | A |
5674390 | Matthews et al. | Oct 1997 | A |
5674404 | Kenley et al. | Oct 1997 | A |
5690831 | Kenley et al. | Nov 1997 | A |
5711883 | Folden et al. | Jan 1998 | A |
5714060 | Kenley et al. | Feb 1998 | A |
5725776 | Kenley et al. | Mar 1998 | A |
5788671 | Johnson | Aug 1998 | A |
5849065 | Wojke | Dec 1998 | A |
5863421 | Peter | Jan 1999 | A |
5928177 | Brugger et al. | Jul 1999 | A |
5938634 | Packard | Aug 1999 | A |
5989423 | Kamen et al. | Nov 1999 | A |
6179801 | Holmes et al. | Jan 2001 | B1 |
6196987 | Holmes et al. | Mar 2001 | B1 |
6200287 | Keller et al. | Mar 2001 | B1 |
6231537 | Holmes et al. | May 2001 | B1 |
6234989 | Brierton et al. | May 2001 | B1 |
6280406 | Dolecek et al. | Aug 2001 | B1 |
6336916 | Bormann et al. | Jan 2002 | B1 |
6337049 | Tamari | Jan 2002 | B1 |
6361518 | Brierton et al. | Mar 2002 | B1 |
6383158 | Utterberg et al. | May 2002 | B1 |
6409696 | Toavs et al. | Jun 2002 | B1 |
6497674 | Steele et al. | Dec 2002 | B1 |
6497676 | Childers et al. | Dec 2002 | B1 |
6514225 | Utterberg et al. | Feb 2003 | B1 |
6536278 | Scagliarini | Mar 2003 | B1 |
6695803 | Robinson et al. | Feb 2004 | B1 |
6725726 | Adolfs et al. | Apr 2004 | B1 |
6730055 | Bainbridge et al. | May 2004 | B2 |
6743201 | Dönig et al. | Jun 2004 | B1 |
6755801 | Utterberg et al. | Jun 2004 | B2 |
6764460 | Dolecek et al. | Jul 2004 | B2 |
6790195 | Steele et al. | Sep 2004 | B2 |
6852090 | Burbank et al. | Feb 2005 | B2 |
6887214 | Levin et al. | May 2005 | B1 |
6979309 | Burbank et al. | Dec 2005 | B2 |
7021148 | Kuhn et al. | Apr 2006 | B2 |
7115107 | Delnevo et al. | Oct 2006 | B2 |
7238164 | Childers et al. | Jul 2007 | B2 |
7476209 | Gara et al. | Jan 2009 | B2 |
7517387 | Chevallet et al. | Apr 2009 | B2 |
7603907 | Reiter et al. | Oct 2009 | B2 |
7621983 | Neri | Nov 2009 | B2 |
7871391 | Folden et al. | Jan 2011 | B2 |
7892331 | Childers et al. | Feb 2011 | B2 |
7892332 | Prisco et al. | Feb 2011 | B2 |
7905853 | Chapman et al. | Mar 2011 | B2 |
8110104 | Crnkovich et al. | Feb 2012 | B2 |
20020014462 | Muller | Feb 2002 | A1 |
20020072718 | Brugger et al. | Jun 2002 | A1 |
20020179527 | Yao | Dec 2002 | A1 |
20040019312 | Childers et al. | Jan 2004 | A1 |
20040238416 | Burbank et al. | Dec 2004 | A1 |
20050054968 | Giannella | Mar 2005 | A1 |
20050126998 | Childers | Jun 2005 | A1 |
20050131332 | Kelly et al. | Jun 2005 | A1 |
20050132826 | Teugels | Jun 2005 | A1 |
20050230292 | Beden et al. | Oct 2005 | A1 |
20070078369 | Tamari | Apr 2007 | A1 |
20070086924 | Moses | Apr 2007 | A1 |
20070106198 | Folden et al. | May 2007 | A1 |
20070112297 | Plahey et al. | May 2007 | A1 |
20070193940 | Duchamp et al. | Aug 2007 | A1 |
20070269340 | Dannenmaier et al. | Nov 2007 | A1 |
20080275364 | Conway et al. | Nov 2008 | A1 |
20090012449 | Lee et al. | Jan 2009 | A1 |
20090071911 | Folden et al. | Mar 2009 | A1 |
20090084721 | Yardimci et al. | Apr 2009 | A1 |
20090101576 | Rohde et al. | Apr 2009 | A1 |
20090216211 | Beden et al. | Aug 2009 | A1 |
20090320684 | Weaver | Dec 2009 | A1 |
20100133189 | Maierhofer et al. | Jun 2010 | A1 |
20100206784 | Weaver et al. | Aug 2010 | A1 |
20100222735 | Plahey et al. | Sep 2010 | A1 |
20100292627 | Caleffi et al. | Nov 2010 | A1 |
20110120946 | Levin et al. | May 2011 | A1 |
Number | Date | Country |
---|---|---|
102005001779 | Sep 2006 | DE |
0 327 136 | Aug 1989 | EP |
0458041 | Nov 1991 | EP |
0 728 509 | Aug 1996 | EP |
0887100 | Dec 1998 | EP |
1 529 545 | May 2005 | EP |
1 547 630 | Jun 2005 | EP |
1 728 526 | Dec 2006 | EP |
1 894 587 | Mar 2008 | EP |
2 226 087 | Sep 2010 | EP |
2003-180834 | Jul 2003 | JP |
2005-530543 | Oct 2005 | JP |
9640322 | Dec 1996 | WO |
WO 0108722 | Feb 2001 | WO |
0150949 | Jul 2001 | WO |
WO 0164312 | Sep 2001 | WO |
WO 0226286 | Apr 2002 | WO |
WO 2004000391 | Dec 2003 | WO |
WO 2005044340 | May 2005 | WO |
WO 2005044341 | May 2005 | WO |
WO 2005065745 | Jul 2005 | WO |
WO 2005077490 | Aug 2005 | WO |
2007050211 | May 2007 | WO |
2008002370 | Jan 2008 | WO |
Entry |
---|
Acu-men, Acute Dialysis Machine Operating Instructions, Software Version 1.0, Fresenius MY acu-men, 1/05.96 (OP), 146 pages. |
Gambro®, “Prismaflex™, Anticipating Critical Care needs and taking our innovative response . . . to new heights”, © 2004, Gambro Inc., Lakewood, CO, 8 pp. |
Gambro®, “DEHP-Free Cartridge Blood Sets”, © Nov. 2004, Gambro, Inc, Lakewood, CO, 4 pp. |
Garnbro®, “Prisma® M60 and M100 Pre-Pump Infusion Sets—Introducing: The unique solution that enables Physicians to choose a predilution method that meets the needs of their patients”, © 2004, Gambro Inc., Lakewood, CO, 4 pp. |
Gambro®, “Prisma® HF 1000, For Increased Filtration Capacity”, © Aug. 2001, Gambro Renal Products, Inc., Lakewood, CO, 2 pp. |
Manns, Markus et al., “The acu-men: A new device for continuous renal replacement therapy in acute renal failure,” Kidney International, vol. 54, pp. 268-274, 1998. |
European Search Report, EP 10154030, Jun. 21, 2010, 3 pages. |
Communication Pursuant to Article 94(3) EPC, EP 10154030.0, Jul. 2, 2010, 4 pages. |
Number | Date | Country | |
---|---|---|---|
20100206784 A1 | Aug 2010 | US |